5 September 2018 - Fibrocell Science today announced that the U.S. FDA has granted fast track designation to FCX-013, the Company’s clinical stage candidate for the treatment of moderate to severe localised scleroderma—a chronic, debilitating genetic skin disorder with no FDA approved therapies.

Previously, the FDA granted Orphan Drug Designation to FCX-013 for the treatment of localised scleroderma and rare paediatric disease designation for the treatment of moderate to severe localised scleroderma.

Read Fibrocell Science press release